Loading clinical trials...
Loading clinical trials...
Browse 1,242 clinical trials for brain cancer. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 1001-1020 of 1,242 trials
NCT01182883
Background: \- IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth. Temsirolimus is a drug that the U.S. Food and Drug Administration has approved to treat advanced renal cell carcinoma in adults. Researchers do not know if the combination of IMC-A12 and temsirolimus will work in children, but want to determine whether these two drugs may be an effective treatment for recurrent tumors. Objectives: * To determine the safety and effectiveness of IMC-A12 and temsirolimus in treating children and adolescents with solid tumors. * To determine possible side effects of the combination of IMC-A12 and temsirolimus. Eligibility: \- Children and adolescents between 12 months and 21 years of age who have solid tumors that have not responded to or have relapsed after standard treatment. Design: * Participants will be screened with a medical history, physical examination, and imaging studies. * Participants will receive IMC-A12 and temsirolimus in 28-day cycles of treatment. IMC-A12 will be given as an infusion over 1 hour, once a week, for 4 weeks. Temsirolimus will also be given after IMC-A12 over 30 minutes, once a week, for 4 weeks. * Participants may continue to receive IMC-A12 and temsirolimus for up to 2 years unless serious side effects develop or the treatment stops being effective. * Participants will have additional physical exams, blood and urine tests, and imaging studies regularly during each treatment cycle. * Participants will be followed at regular intervals after the end of the study to collect tumor response and progression data....
NCT00694330
This research study is testing the safety of a vaccination of cells called GM-K562 cells mixed with the participants own irradiated tumor cells. The GM-K562 cells have been modified in the laboratory to secrete the protein GM-CSF. This protein can be effective in stimulating an immune response to cancer. This newly developed vaccine may stop cancer cells from growing.